Large clinical study presented at sts 2021 finds 79% survival rate with impella 5.5 with smartassist

Danvers, mass.--(business wire)--abiomed (nasdaq: abmd) announces a large study of 356 patients treated with impella 5.5 with smartassist at 16 u.s. and german centers found a 79% survival rate at explant. a majority of surviving patients recovered their native heart function without needing further mechanical support or a heart transplant. the study is the first large, multicenter experience examining survival rates with impella 5.5 with smartassist support. it was presented at the society of
ABMD Ratings Summary
ABMD Quant Ranking